Elevance Health (ELV) has a mix of performance outcomes in the bio-tech market. The financial results for Q2 2024 reveal higher than forthseen profit due to lower benefit expenses and higher premium collection. Despite this, the firm saw a fall in its share price and even underperformed in comparison to its competitors. Overall, Elevance Health shares had a mixed response to the company's Q2 earnings. A strong value stock outlook has been suggested by financial analysts following the Q2 results release. Despite Medicaid pressure and lowered peer valuations, the company's annual guidance is upheld following the strong Q2 earnings. Investment giants like Intech Investment Management LLC and Thoroughbred Financial Services LLC reduced their shareholdings in ELV. Meanwhile, firms like Catalytic Wealth RIA LLC stepped in to buy shares. The Bank of America maintained a 'Neutral' rating with downward adjustments being made to price targets by TD Cowen and Barclays while Truist and Royal Bank of Canada raised theirs to $620.00. Elevance Health shows signs of becoming a dividend growth machine with the company declaring a quarterly dividend of $1.63.
Elevance Health ELV News Analytics from Mon, 01 Apr 2024 07:00:00 GMT to Sun, 21 Jul 2024 18:41:03 GMT -
Rating 0.5
- Innovation 3
- Information 8
- Rumor -1
